We’re supporting clients through every stage of their brand and product lifecycle.
Our centers of expertise span therapeutic areas, markets and geographies, and are underpinned by these four core research principles:
A new price control methodology for patented drugs could potentially affect Colombia’s market attractiveness.
Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies.
Learn what Tania Rodrigues found most impactful with regards to market access and pricing and reimbursement at the recent Advanced Therapies Congress.
Marc Garcia and Michael Burnill from Research Partnership’s Market Access team attended the 2023 World Evidence, Pricing and Access conference.
Find out about our paper about payers perspectives on the acceptability of surrogate endpoints for acute conditions managed in the ICU.
Research Partnership reviews why the path to commercialization for the half a dozen approvals in Europe over the last few years has not been smooth.
Tania Rodrigues reflects on sessions and roundtables from the conference where hot topics related to advanced therapies were discussed.
Rachel Howard, Tania Rodrigues, and Rebeca Nana Barrantes recently joined over a thousand delegates in attending the 2022 World EPA Congress.
Chimeric antigen receptor (CAR)-T continues to take center stage as a paradigm shift in the treatment of cancer.
Our client was developing a CAR-T therapy in MM across multiple lines of therapy.
We recently caught up with Dr Xavier Tello, to get an update on the status of these reforms and explore their implications for the pharma industry.
Preparing to launch a new asset and in need of demand assessment research? Download our pre-launch checklist.
Rapport is our monthly newsletter where we share our latest expertise and experience.
